Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.39 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285982 | 0.91 | DRD3 (0.41) | DRD3KMT2AMEN1HCRTR2HCRTR1 | |
| SCHEMBL4286026 | 0.87 | HPGD (0.49) | DRD3KMT2AHPGD | |
| SCHEMBL4285755 | 0.86 | KDM4E (0.51) | KMT2AMEN1HPGD | |
| SCHEMBL4285970 | 0.85 | KDM4E (0.51) | DRD3KMT2AHCRTR2HCRTR1 | |
| SCHEMBL4287638 | 0.85 | LMNA (0.50) | DRD3KMT2AMEN1HPGD | |
| SCHEMBL4284656 | 0.85 | FFAR1 (0.42) | KMT2AMEN1HCRTR2HCRTR1 | |
| SCHEMBL4294041 | 0.85 | HCRTR1 (0.40) | KMT2AMEN1HCRTR2HCRTR1HPGD | |
| SCHEMBL4289383 | 0.85 | RAB9A (0.43) | KMT2AMEN1HPGD | |
| SCHEMBL4281669 | 0.85 | KDM4E (0.39) | DRD3KMT2AMEN1HCRTR2HCRTR1 | |
| SCHEMBL4287265 | 0.85 | KDM4E (0.45) | KMT2AMEN1TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | DRD3 3476/4885KMT2A 1049/4885MEN1 1254/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | DRD3 3476/4885KMT2A 1049/4885MEN1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.